EXPRESSION OF ISOCITRATE DEHYDROGENASE 1 MUTATION BY R 132 H ANTIBODY CLONE H09 IN GRADE II-IV ASTROCYTOMA AND SECONDARY GLIOBLASTOMA

PRAGNYA PARAMITA MISHRA; TAPAS RANJAN MISHRA; PRIYA KUMARI; PREMANAND PANDA

doi:10.22159/ajpcr.2025v18i7.54669

Authors

PRAGNYA PARAMITA MISHRA Department of Pathology, Hi-tech MCH, Rourkela, Odisha, India
TAPAS RANJAN MISHRA Department of Pathology, Government Medical College and Hospital, Phulbani, Odisha, India
PRIYA KUMARI Department of Pathology, Hi-tech MCH, Rourkela, Odisha, India.
PREMANAND PANDA Department of Radiology, JP Hospital and Research Centre, Rourkela, Odisha, India.

DOI:

https://doi.org/10.22159/ajpcr.2025v18i7.54669

Keywords:

Astrocytoma, Glioblastoma, Isocitrate dehydrogenase 1 immunohistochemistry, Prognosis

Abstract

Objective: Based on their development patterns, behaviors, and shared genetic driver mutations in the isocitrate dehydrogenase (IDH1) and IDH2 genes, diffusely infiltrating gliomas are categorized. There are three types of astrocyte tumors: Not otherwise specified (NOS), IDH-mutant, and IDH-wildtype. About 10% of cases of low-grade glioma that arise in young people and have an IDH1 mutation progress to secondary glioblastoma (sGBM). Hence, IDH sequencing is highly recommended. The aim of the study is to show the presence of IDH1 mutation in all grades of astrocytomas and sGBM and classify them using IDH1 mutation as per the new World Health Organization central nervous system classification.

Methods: The study was conducted in the Department of Pathology, Hitech Medical College and Hospital, Rourkela and was a single-center prospective cross-sectional study that started in January 2023 and ended in December 2024. Paraffin-embedded tissue sections were subjected to immunohistochemistry (IHC) using IDH1 R 132 H CLONE H09 as per standard protocol, and slides were studied. All patients are followed through telephonic conversation.

Results: A total of 47 cases were received over the study period. Out of the total cases, 60% of grade 2 astrocytoma and 50% of cases of grade 3 astrocytoma are IDH1 positive. Of 24 cases of grade 4 astrocytoma, one case is IDH1 positive, whereas all 03 cases of sGBM are positive. Statistically significant results were obtained in the distribution of tumors and IDH1 mutation positivity in grade 4 astrocytoma.

Conclusions: Classified astrocytomas into IDH mutant and wild-type categories, thereby reducing NOS categories. IDH1 IHC is considered a surrogate marker in assessing the IDH1 mutational status.

Downloads

Download data is not yet available.

References

Mohamed AA, Alshaibi R, Faragalla S, Mohamed Y, Lucke-Wold B. Updates on management of gliomas in the molecular age. World J Clin Oncol. 2024 Feb 24;15(2):178-94. doi: 10.5306/wjco.v15.i2.178, PMID 38455131

Giunchedi P, Gavini E, Bonferoni MC. Nose-to-brain delivery. Pharmaceutics. 2020;12(2):138. doi: 10.3390/pharmaceutics12020138, PMID 32041344

Burger PC, Scheithauer BW, Paulus W, Szymas J, Giannini C, Kleihues P. Pilocytic astrocytoma. In: Kleihues P, Cavenee WK, editors. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000. p. 45-51.

Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96. doi: 10.1056/NEJMoa043330, PMID 15758009

Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492-507. [Erratum. N Engl J Med. 2008;359(877)].

Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-8. doi: 10.1038/nature07385, PMID 18772890

Preusser M, Capper D, Hartmann C, Euro-CNS Research Committee. IDH testing in diagnostic neuropathology: Review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol. 2011 Sep-Oct;30(5):217-30. doi: 10.5414/np300422, PMID 21955925

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 Mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765-73.

Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella- Branger D, Cavenee WK, et al. The 2016 World health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016;131(6):803-20. doi: 10.1007/s00401-016-1545-1, PMID 27157931

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-74. doi: 10.1007/s00401-009-0561-9, PMID 19554337

Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245-54.